Taking tumor staging, PSA measurement and the Gleason score together, clinical staging before the MRI scan resulted in a risk group distribution for low, intermediate and high-risk of 11.5%, 42.6% and 43.4%, respectively according the NCCN prostate cancer guidelines. The gene discussed is KLK3; the disease is neoplasm.